title: Dynamics of reactive oxygen metabolites and biological antioxidant potential in the acute stage of Kawasaki disease.
abstract: BACKGROUND
  The dynamics of oxidation/reduction control system activities using reactive oxygen metabolites (ROM) and biological antioxidant potential (BAP) in acute stage patients was evaulated to understand the mechanism of vascular injury and remodeling in Kawasaki disease (KD).
  
  
  RESULTS
  ROM, BAP, high-sensitivity C-reactive protein (hs-CRP), interleukin-1,2,6, and tumour necrosis factor-α in 19 KD patients were measured. ROM decreased in good correlation only with hs-CRP (P<0.05) at 2 weeks after intravenous immunoglobulin (IVIG). Patients were further classified as responding well (Group A) or responding poorly (Group B) to IVIG. Both treatment groups had significantly higher ROM values than the control group (P<0.01). ROM decreased in Group A both immediately and 2 weeks after the IVIG treatment (P<0.05), but it did not decrease in Group B until 2 weeks post-treatment (P<0.01). BAP levels were unremarkable in Group A, but were significantly lower in Group B than in both other groups (P<0.05). BAP increased in Group A 2 weeks after IVIG treatment (P<0.01), but remained low in Group B (P<0.01).
  
  
  CONCLUSIONS
  Acute stage KD patients suffer from obvious hyperoxidant stress, and improved in response to IVIG treatment in most patients. Blood BAP level might be a useful index for predicting responsiveness to IVIG the treatment.
authors.affiliation: Department of Pediatric Cardiology and Nephrology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
authors.forename: Tomoyo
authors.initials: T
authors.lastname: Yahata
authors.forename: Chinatsu
authors.initials: C
authors.lastname: Suzuki
authors.forename: Akiko
authors.initials: A
authors.lastname: Hamaoka
authors.forename: Maiko
authors.initials: M
authors.lastname: Fujii
authors.forename: Kenji
authors.initials: K
authors.lastname: Hamaoka
mesh_terms: D000208:Acute Disease; D000975:Antioxidants / Q000378:metabolism*; D016022:Case-Control Studies; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011237:Predictive Value of Tests; D011379:Prognosis; D017382:Reactive Oxygen Species / Q000378:metabolism*; D016896:Treatment Outcome; D014657:Vasculitis / Q000209:etiology
chemical_list: D000975:Antioxidants; D016756:Immunoglobulins, Intravenous; D017382:Reactive Oxygen Species